Insider Transactions in Q2 2021 at Fate Therapeutics Inc (FATE)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2021
|
Mark Plavsic Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+50.0%
|
-
|
|
Jun 14
2021
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
25,000
-7.29%
|
$2,225,000
$89.85 P/Share
|
|
Jun 14
2021
|
Bahram Valamehr Chief R&D Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+9.72%
|
$50,000
$2.82 P/Share
|
|
Jun 02
2021
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
John Mendlein |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+1.65%
|
-
|
|
Jun 02
2021
|
Shefali Agarwal |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
Karin Jooss |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
Robert S Epstein |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
William H Rastetter |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+4.34%
|
-
|
|
Jun 02
2021
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,681
+50.0%
|
-
|
|
Jun 02
2021
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,681
+0.02%
|
-
|
|
May 20
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-4.83%
|
$1,540,000
$77.16 P/Share
|
|
May 20
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.61%
|
$80,000
$4.84 P/Share
|
|
Apr 23
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-7.08%
|
$2,550,000
$85.24 P/Share
|
|
Apr 23
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+2.35%
|
$120,000
$4.73 P/Share
|
|
Apr 22
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-7.08%
|
$2,550,000
$85.54 P/Share
|
|
Apr 22
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.61%
|
$60,000
$2.73 P/Share
|
|
Apr 16
2021
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,275
-1.63%
|
$271,825
$83.04 P/Share
|
|
Apr 01
2021
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
30,000
-3.0%
|
$2,520,000
$84.09 P/Share
|
|
Apr 01
2021
|
Cindy Tahl General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+9.23%
|
$150,000
$5.39 P/Share
|